Study

Translating medication effects for alcohol use disorder across preclinical, human laboratory, and clinical trial outcomes using meta-analysis

2025 · systematic-review-or-meta-analysis · peer reviewed: yes · record 40691154 · PubMed

7 findings kept from this study. Each is one sentence comparing an animal with a human, extracted from the full text, checked against the located page, and adjudicated against the review's definition of an animal-versus-human comparison.

Medications that reduced alcohol preference in preclinical 2-BC studies were associated with lower return to drinking in human clinical trials, with a linear slope of 0.04.

Concordant · level A · no species named · psychiatry/addiction · 0.04

“For the preclinical 2-BC preference endpoint, the linear slope is statistically significant for return to any drinking in RCTs (β = 0.04, SE = 0.02, p=0.004; Fig. 2B), such that medications that reduced alcohol preference in preclinical 2-BC studies were associated with lower return to drinking in RCTs.”
page 5

Medications that reduced animal responding during reinstatement in preclinical studies showed a trend-level significance for lower return to heavy drinking in human clinical trials, with a linear slope of 0.20.

Concordant · level A · no species named · psychiatry/addiction · 0.2

“For the preclinical active lever presses endpoint within reinstatement studies, the linear slope reached trend-level significance for return to heavy drinking in RCTs (β = 0.20, SE = 0.13, p = 0.05; Fig. 2C), such that medications the reduced animal responding during reinstatement were associated with lower return to drinking in RCTs.”
page 5

Medication effects on 2-BC alcohol consumption in preclinical models were not statistically significant for return to any drinking in human clinical trials, with a linear slope of -0.05.

Discordant · level A · no species named · psychiatry/addiction · -0.05

“For the preclinical 2-BC consumption endpoint, the linear slope is not statistically significant for return to any drinking in RCTs (β = -0.05, SE = 0.02, p = 0.98; Fig. 2A).”
page 4

Preclinical medications findings were not associated with medication effects on cue-induced craving in the human laboratory.

Discordant · level A · no species named · psychiatry/addiction

“Preclinical medications findings were not associated with medication effects on cue-induced craving in the human laboratory.”
page 1

Medication effects on 2-BC alcohol consumption in preclinical models were not statistically significant for return to heavy drinking in human clinical trials, with a linear slope of 0.01.

Discordant · level A · no species named · psychiatry/addiction · 0.01

“For the preclinical 2-BC consumption endpoint, the linear slope is not statistically significant for return to heavy drinking in RCTs (ẞ = 0.01, SE = 0.04, p = 0.44; Fig. 3A).”
page 5

Medication effects on 2-BC alcohol preference in preclinical models were not statistically significant for return to heavy drinking in human clinical trials, with a linear slope of 0.06.

Discordant · level A · no species named · psychiatry/addiction · 0.06

“For the preclinical 2-BC preference endpoint, the linear slope is not statistically significant for return to heavy drinking in RCTs (β= 0.06, SE = 0.06, p = 0.17; Fig. 3B).”
page 5

Medication effects on operant reinstatement in preclinical models were not statistically significant for return to heavy drinking in human clinical trials, with a linear slope of 0.19.

Discordant · level A · no species named · psychiatry/addiction · 0.19

“For the preclinical active lever presses endpoint within reinstatement studies, the linear slope is not statistically significant for return to heavy drinking in RCTs (ẞ = 0.19, SE = 0.13, p = 0.08; Fig. 3C).”
page 5